Skip to main content
Erschienen in: Pituitary 3/2016

12.02.2016

Arterial properties in acromegaly: relation to disease activity and associated cardiovascular risk factors

verfasst von: Marianna Yaron, Elena Izkhakov, Jessica Sack, Ibrahim Azzam, Etty Osher, Karen Tordjman, Naftali Stern, Yona Greenman

Erschienen in: Pituitary | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Acromegaly is associated with increased cardiovascular morbidity and mortality when inadequately treated, which may be secondary to associated comorbidities or to direct IGF-1 effects on the cardiovascular system. By using a control group carefully matched for traditional cardiovascular risk factors, we aimed to assess the direct contribution of disease activity and IGF-1 levels to arterial damage as assessed by measurements of arterial stiffness and endothelial function.

Methods

Twenty-nine subjects with acromegaly (11 males, 52 ± 14 year; 15 active acromegaly) and 24 matched controls underwent evaluation of large and small artery compliance using applanation tonometry, pulse wave velocity (PWV), augmentation index (Alx), carotid ultrasonography intima-media thickness, (IMT) and flow-mediated dilatation (FMD).

Results

IGF-1 expressed as times the upper limit of the normal range (x ULN) was 2.2 ± 1.1 in patients with active disease versus 0.7 ± 0.2 in patients in remission. Irrespective of disease activity, FMD was lower in patients with acromegaly than in control subjects, (3.4 ± 2.7 % in active acromegaly, 4.4 ± 3.3 % in controlled acromegaly and 7.5 ± 3.8 % in controls; p = 0.004). There were no significant differences in PWV, Alx, and IMT between groups. A positive correlation was found between IGF-1× ULN and IMT (r = 0.4; P = 0.02). Asymmetric dimethylarginine (ADMA), a novel cardiovascular risk factor, was positively correlated to arterial stiffness (r = 0.46; p = 0.017) and negatively with small vessel compliance (r = −0.44, p = 0.02).

Conclusions

Patients with acromegaly have significantly impaired endothelial function as assessed by FMD, but other tested vascular parameters were similar to a control group that was adequately matched for cardiovascular risk factors.
Literatur
1.
Zurück zum Zitat Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, Gomez JM, Halperin I, Lucas-Morante T, Moreno B, Obiols G, de Pablos P, Paramo C, Pico A, Torres E, Varela C, Vazquez JA, Zamora J, Albareda M, Gilabert M (2004) Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 151:439–446CrossRefPubMed Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, Gomez JM, Halperin I, Lucas-Morante T, Moreno B, Obiols G, de Pablos P, Paramo C, Pico A, Torres E, Varela C, Vazquez JA, Zamora J, Albareda M, Gilabert M (2004) Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 151:439–446CrossRefPubMed
2.
Zurück zum Zitat Arosio M, Reimondo G, Malchiodi E, Berchialla P, Borraccino A, De Marinis L, Pivonello R, Grottoli S, Losa M, Cannavò S, Minuto F, Montini M, Bondanelli M, De Menis E, Martini C, Angeletti G, Velardo A, Peri A, Faustini-Fustini M, Tita P, Pigliaru F, Borretta G, Scaroni C, Bazzoni N, Bianchi A, Appetecchia M, Cavagnini F, Lombardi G, Ghigo E, Beck-Peccoz P, Colao A, Terzolo M, Italian Study Group of Acromegaly (2012) Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol 167:189–198PubMed Arosio M, Reimondo G, Malchiodi E, Berchialla P, Borraccino A, De Marinis L, Pivonello R, Grottoli S, Losa M, Cannavò S, Minuto F, Montini M, Bondanelli M, De Menis E, Martini C, Angeletti G, Velardo A, Peri A, Faustini-Fustini M, Tita P, Pigliaru F, Borretta G, Scaroni C, Bazzoni N, Bianchi A, Appetecchia M, Cavagnini F, Lombardi G, Ghigo E, Beck-Peccoz P, Colao A, Terzolo M, Italian Study Group of Acromegaly (2012) Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol 167:189–198PubMed
3.
Zurück zum Zitat Jayasena C, Comninos A, Clarke H, Donaldson M, Meeran K, Dhillo W (2011) The effects of long term GH and IGF-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly. Clin Endocrinol 75:220–225CrossRef Jayasena C, Comninos A, Clarke H, Donaldson M, Meeran K, Dhillo W (2011) The effects of long term GH and IGF-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly. Clin Endocrinol 75:220–225CrossRef
4.
Zurück zum Zitat López-Velasco R, Escobar-Morreale HF, Vega B, Villa E, Sancho JM, Moya-Mur JL, García-Robles R (1997) Cardiac involvement in acromegaly: specific myocardiopathy or consequence of systemic hypertension? J Clin Endocrinol Metab 82:1047PubMed López-Velasco R, Escobar-Morreale HF, Vega B, Villa E, Sancho JM, Moya-Mur JL, García-Robles R (1997) Cardiac involvement in acromegaly: specific myocardiopathy or consequence of systemic hypertension? J Clin Endocrinol Metab 82:1047PubMed
5.
Zurück zum Zitat Ben-Shlomo Y, Spears M, Boustred C, May M, Anderson SG, Benjamin EJ, Boutouyrie P, Cameron J, Chen CH, Cruickshank JK, Hwang SJ, Lakatta EG, Laurent S, Maldonado J, Mitchell G, Najjar S, Newman AB, Ohishi M, Pannier B, Pereira T, Vasan RS, Shokawa T, Sutton-Tyrell K, Verbeke F, Wang KL, Webb DJ, Willum Hansen T, Zoungas S (2014) Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol 63:636–646CrossRefPubMedPubMedCentral Ben-Shlomo Y, Spears M, Boustred C, May M, Anderson SG, Benjamin EJ, Boutouyrie P, Cameron J, Chen CH, Cruickshank JK, Hwang SJ, Lakatta EG, Laurent S, Maldonado J, Mitchell G, Najjar S, Newman AB, Ohishi M, Pannier B, Pereira T, Vasan RS, Shokawa T, Sutton-Tyrell K, Verbeke F, Wang KL, Webb DJ, Willum Hansen T, Zoungas S (2014) Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol 63:636–646CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr (1999) Carotid artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular health study collaborative research group. New Engl J Med 340:14–22CrossRefPubMed O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr (1999) Carotid artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular health study collaborative research group. New Engl J Med 340:14–22CrossRefPubMed
7.
Zurück zum Zitat Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard Herman H, Herrington D, International Brachial Artery Reactivity Task Force (2002) Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the international brachial artery reactivity task force. J Am Coll Cardiology 39:257–265CrossRef Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard Herman H, Herrington D, International Brachial Artery Reactivity Task Force (2002) Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the international brachial artery reactivity task force. J Am Coll Cardiology 39:257–265CrossRef
8.
Zurück zum Zitat Colao A, Spiezia S, Cerbone G, Pivonello R, Marzullo P, Ferone D, Di Somma C, Assanti AP, Lombardi G (2001) Increased arterial intima-media thickness by B-M mode echo doppler ultrasonography in acromegaly. Clin Endocrinol (Oxf) 54:515–524CrossRef Colao A, Spiezia S, Cerbone G, Pivonello R, Marzullo P, Ferone D, Di Somma C, Assanti AP, Lombardi G (2001) Increased arterial intima-media thickness by B-M mode echo doppler ultrasonography in acromegaly. Clin Endocrinol (Oxf) 54:515–524CrossRef
9.
Zurück zum Zitat Colao A, Spinelli L, Cuocolo A, Spiezia S, Pivonello R, di Somma C, Bonaduce D, Salvatore M, Lombardi G (2002) Cardiovascular consequences of early-onset growth hormone excess. J Clin Endocrinol Metab 87:3097–3104CrossRefPubMed Colao A, Spinelli L, Cuocolo A, Spiezia S, Pivonello R, di Somma C, Bonaduce D, Salvatore M, Lombardi G (2002) Cardiovascular consequences of early-onset growth hormone excess. J Clin Endocrinol Metab 87:3097–3104CrossRefPubMed
10.
Zurück zum Zitat Brevetti G, Marzullo P, Silvestro A, Pivonello R, Oliva G, di Somma C, Lombardi G, Colao A (2002) Early vascular alterations in acromegaly. J Clin Endocrinol Metab 87:3174–3179CrossRefPubMed Brevetti G, Marzullo P, Silvestro A, Pivonello R, Oliva G, di Somma C, Lombardi G, Colao A (2002) Early vascular alterations in acromegaly. J Clin Endocrinol Metab 87:3174–3179CrossRefPubMed
11.
Zurück zum Zitat Yeboah J, Folsom AR, Burke GL, Johnson C, Polak JF, Post W, Lima JA, Crouse JR, Herrington DM (2009) Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation 120:502–509CrossRefPubMedPubMedCentral Yeboah J, Folsom AR, Burke GL, Johnson C, Polak JF, Post W, Lima JA, Crouse JR, Herrington DM (2009) Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation 120:502–509CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Paisley AN, Banerjee M, Rezai M, Schofield RE, Balakrishnannair S, Herbert A, Lawrance Jeremy AL, Trainer PJ, Cruickshank JK (2011) Changes in arterial stiffness but not carotid intimal thickness in acromegaly. J Clin Endocrinol Metab 96:1486–1492CrossRefPubMed Paisley AN, Banerjee M, Rezai M, Schofield RE, Balakrishnannair S, Herbert A, Lawrance Jeremy AL, Trainer PJ, Cruickshank JK (2011) Changes in arterial stiffness but not carotid intimal thickness in acromegaly. J Clin Endocrinol Metab 96:1486–1492CrossRefPubMed
13.
Zurück zum Zitat Bogazzi F, Battolla L, Spinelli C, Rossi G, Gavioli S, Di Bello V, Cosci C, Sardella C, Volterrani D, Talini E, Pepe P, Falaschi F, Mariani G, Martino E (2007) Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study. J Clin Endocrinol Metab 92:4271–4277CrossRefPubMed Bogazzi F, Battolla L, Spinelli C, Rossi G, Gavioli S, Di Bello V, Cosci C, Sardella C, Volterrani D, Talini E, Pepe P, Falaschi F, Mariani G, Martino E (2007) Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study. J Clin Endocrinol Metab 92:4271–4277CrossRefPubMed
14.
Zurück zum Zitat Akutsu H, Kreutzer J, Wasmeier G, Ropers D, Rost C, Möhlig M, Wallaschofski H, Buchfelder M, Schöfl C (2010) Acromegaly per se does not increase the risk for coronary artery disease. Eur J Endocrinol 162:879–886CrossRefPubMed Akutsu H, Kreutzer J, Wasmeier G, Ropers D, Rost C, Möhlig M, Wallaschofski H, Buchfelder M, Schöfl C (2010) Acromegaly per se does not increase the risk for coronary artery disease. Eur J Endocrinol 162:879–886CrossRefPubMed
15.
Zurück zum Zitat Dos Santos Silva CM, Lima GA, Volschan IC, Gottlieb I, Kasuki L, Neto LV, Gadelha MR (2015) Low risk of coronary artery disease in patients with acromegaly. Endocrine 50(3):749–755CrossRefPubMed Dos Santos Silva CM, Lima GA, Volschan IC, Gottlieb I, Kasuki L, Neto LV, Gadelha MR (2015) Low risk of coronary artery disease in patients with acromegaly. Endocrine 50(3):749–755CrossRefPubMed
16.
Zurück zum Zitat Berg C, Petersenn S, Lahner H, Herrmann BL, Buchfelder M, Droste M, Stalla GK, Strasburger CJ, Roggenbuck U, Lehmann N, Moebus S, Jöckel KH, Möhlenkamp S, Erbel R, Saller B, Mann K, Investigative Group of the Heinz Nixdorf Recall Study and the German Pegvisomant Observational Study Board and Investigators (2010) Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control. J Clin Endocrinol Metab 95:3648–3656CrossRefPubMed Berg C, Petersenn S, Lahner H, Herrmann BL, Buchfelder M, Droste M, Stalla GK, Strasburger CJ, Roggenbuck U, Lehmann N, Moebus S, Jöckel KH, Möhlenkamp S, Erbel R, Saller B, Mann K, Investigative Group of the Heinz Nixdorf Recall Study and the German Pegvisomant Observational Study Board and Investigators (2010) Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control. J Clin Endocrinol Metab 95:3648–3656CrossRefPubMed
17.
Zurück zum Zitat Cannavo S, Almoto B, Cavalli G, Squadrito S, Romanello G, Vigo MT, Fiumara F, Benvenga S, Trimarchi F (2006) Acromegaly and coronary disease: an integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography. J Clin Endocrinol Metab 91:3766–3772CrossRefPubMed Cannavo S, Almoto B, Cavalli G, Squadrito S, Romanello G, Vigo MT, Fiumara F, Benvenga S, Trimarchi F (2006) Acromegaly and coronary disease: an integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography. J Clin Endocrinol Metab 91:3766–3772CrossRefPubMed
18.
Zurück zum Zitat Yaron M, Greenman Y, Rosenfeld JB, Izkhakov E, Limor R, Osher E, Shenkerman G, Tordjman K, Stern N (2009) Effect of testosterone replacement therapy on arterial stiffness in older hypogonadal men. Eur J Endocrinol 160:839–846CrossRefPubMed Yaron M, Greenman Y, Rosenfeld JB, Izkhakov E, Limor R, Osher E, Shenkerman G, Tordjman K, Stern N (2009) Effect of testosterone replacement therapy on arterial stiffness in older hypogonadal men. Eur J Endocrinol 160:839–846CrossRefPubMed
19.
Zurück zum Zitat Wilkinson IB, MacCallum H, Flint L, Cockcroft JR, Newby DE, Webb DJ (2000) The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol 525:263–270CrossRefPubMedPubMedCentral Wilkinson IB, MacCallum H, Flint L, Cockcroft JR, Newby DE, Webb DJ (2000) The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol 525:263–270CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Asmar R, Benetos A, Topoucian J, Laurent P, Pannier B, Brisac AM, Target R, Levy BI (1995) Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension 26:485–490CrossRefPubMed Asmar R, Benetos A, Topoucian J, Laurent P, Pannier B, Brisac AM, Target R, Levy BI (1995) Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension 26:485–490CrossRefPubMed
21.
Zurück zum Zitat Cohn JN, Finkelstein S, McVeigh G, Morgan D, LeMay L, Robinson J, Mock J (1995) Noninvasive pulse wave analysis for the early detection of vascular disease. Hypertension 26:503–508CrossRefPubMed Cohn JN, Finkelstein S, McVeigh G, Morgan D, LeMay L, Robinson J, Mock J (1995) Noninvasive pulse wave analysis for the early detection of vascular disease. Hypertension 26:503–508CrossRefPubMed
22.
Zurück zum Zitat Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, Najjar SS, Rembold CM, Post WS, ASE Consensus Statement. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography (2008) Carotid intima media-thickness task force endorsed by the society of vascular medicine. J Am Soc Echocardiogr 21:93–111CrossRefPubMed Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, Najjar SS, Rembold CM, Post WS, ASE Consensus Statement. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography (2008) Carotid intima media-thickness task force endorsed by the society of vascular medicine. J Am Soc Echocardiogr 21:93–111CrossRefPubMed
23.
Zurück zum Zitat Brabant G, von zur Mu¨ hlen A, Ranke MB, Kratzsch J, Kiess W, Ketelslegers JM, Wilhelmsen L, Hulthen L, Saller B, Mattson A, Wilde J, Schemer R, Kann P, German KIMS Board (2003) Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicentre study. Horm Res 60:53–60CrossRefPubMed Brabant G, von zur Mu¨ hlen A, Ranke MB, Kratzsch J, Kiess W, Ketelslegers JM, Wilhelmsen L, Hulthen L, Saller B, Mattson A, Wilde J, Schemer R, Kann P, German KIMS Board (2003) Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicentre study. Horm Res 60:53–60CrossRefPubMed
24.
Zurück zum Zitat Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRefPubMed Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRefPubMed
25.
Zurück zum Zitat Teerlink T (2005) Determination of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine in biological samples by HPLC. Methods Mol Med 108:263–274PubMed Teerlink T (2005) Determination of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine in biological samples by HPLC. Methods Mol Med 108:263–274PubMed
26.
Zurück zum Zitat Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP (2008) Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 93:61–67CrossRefPubMed Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP (2008) Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 93:61–67CrossRefPubMed
27.
Zurück zum Zitat Colao A, Auriemma RS, Galdiero M, Lombardi G, Pivonello R (2009) Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J Clin Endocrinol Metab 94:3746–3756CrossRefPubMed Colao A, Auriemma RS, Galdiero M, Lombardi G, Pivonello R (2009) Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J Clin Endocrinol Metab 94:3746–3756CrossRefPubMed
28.
Zurück zum Zitat Colao A, Pivonello R, Galderisi M, Cappabianca P, Auriemma RS, Galdiero M, Cavallo LM, Esposito F, Lombardi G (2008) Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. J Clin Endocrinol Metab 93:2639–2646CrossRefPubMed Colao A, Pivonello R, Galderisi M, Cappabianca P, Auriemma RS, Galdiero M, Cavallo LM, Esposito F, Lombardi G (2008) Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. J Clin Endocrinol Metab 93:2639–2646CrossRefPubMed
29.
Zurück zum Zitat Sakai H, Tsuchiya K, Nakayama C, Iwashima F, Izumiyama H, Doi M, Yoshimoto T, Tsujino M, Yamada S, Hirata Y (2008) Izumiyama HImprovement of endothelial dysfunction in acromegaly after transsphenoidal surgery. Endocr J 55:853–859CrossRefPubMed Sakai H, Tsuchiya K, Nakayama C, Iwashima F, Izumiyama H, Doi M, Yoshimoto T, Tsujino M, Yamada S, Hirata Y (2008) Izumiyama HImprovement of endothelial dysfunction in acromegaly after transsphenoidal surgery. Endocr J 55:853–859CrossRefPubMed
30.
Zurück zum Zitat Ronchi CL, Varca V, Beck-Peccoz P, Orsi E, Donadio F, Baccarelli A, Giavoli C, Ferrante E, Lania A, Spada A, Arosio M (2006) Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. J Clin Endocrinol Metab 91:121–128CrossRefPubMed Ronchi CL, Varca V, Beck-Peccoz P, Orsi E, Donadio F, Baccarelli A, Giavoli C, Ferrante E, Lania A, Spada A, Arosio M (2006) Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. J Clin Endocrinol Metab 91:121–128CrossRefPubMed
31.
Zurück zum Zitat Annamalai AK, Webb A, Kandasamy N, Elkhawad M, Moir S, Khan F, Maki-Petaja K, Gayton EL, Strey CH, O’Toole S, Ariyaratnam S, Halsall DJ, Chaudhry AN, Berman L, Scoffings DJ, Antoun NM, Dutka DP, Wilkinson IB, Shneerson JM, Pickard JD, Simpson HL, Gurnell M (2013) A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgicalsomatostatin receptor ligand therapy. J Clin Endocrinol Metab 98:1040–1050CrossRefPubMed Annamalai AK, Webb A, Kandasamy N, Elkhawad M, Moir S, Khan F, Maki-Petaja K, Gayton EL, Strey CH, O’Toole S, Ariyaratnam S, Halsall DJ, Chaudhry AN, Berman L, Scoffings DJ, Antoun NM, Dutka DP, Wilkinson IB, Shneerson JM, Pickard JD, Simpson HL, Gurnell M (2013) A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgicalsomatostatin receptor ligand therapy. J Clin Endocrinol Metab 98:1040–1050CrossRefPubMed
32.
Zurück zum Zitat Akgul E, Tokgozoglu SL, Erbas T, Kabakci G, Aytemir K, Haznedaroglu I, Oto A, Kes SS (2010) Evaluation of the impact of treatment on endothelial function and cardiac performance in acromegaly. Echocardiography 27:990–996CrossRefPubMed Akgul E, Tokgozoglu SL, Erbas T, Kabakci G, Aytemir K, Haznedaroglu I, Oto A, Kes SS (2010) Evaluation of the impact of treatment on endothelial function and cardiac performance in acromegaly. Echocardiography 27:990–996CrossRefPubMed
33.
Zurück zum Zitat De Martino MC, Auriemma RS, Brevetti G, Vitale G, SchianoV Galdiero M, Grasso L, Lombardi G, Colao A, Pivonello R (2010) The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues. J Endocrinol Invest 33:663–670CrossRefPubMed De Martino MC, Auriemma RS, Brevetti G, Vitale G, SchianoV Galdiero M, Grasso L, Lombardi G, Colao A, Pivonello R (2010) The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues. J Endocrinol Invest 33:663–670CrossRefPubMed
34.
Zurück zum Zitat Otsuki M, Kasayama S, Yamamoto H, Saito H, Sumitani S, Kouhara H, Saitoh Y, Ohnishi T, Arita N (2001) Characterization of premature atherosclerosis of carotid arteries in acromegalic patients. Clin Endocrinol 54:791–796CrossRef Otsuki M, Kasayama S, Yamamoto H, Saito H, Sumitani S, Kouhara H, Saitoh Y, Ohnishi T, Arita N (2001) Characterization of premature atherosclerosis of carotid arteries in acromegalic patients. Clin Endocrinol 54:791–796CrossRef
35.
Zurück zum Zitat Nemes A, Csanády M, Forster T (2012) Aortic stiffness is increased in acromegaly regardless the method of assessment. Int J Cardiol 154:202–203CrossRefPubMed Nemes A, Csanády M, Forster T (2012) Aortic stiffness is increased in acromegaly regardless the method of assessment. Int J Cardiol 154:202–203CrossRefPubMed
36.
Zurück zum Zitat Nemes A, Gavallér H, Csajbók E, Julesz J, Forster T, Csanády M (2008) Aortic stiffness is increased in acromegaly—a transthoracic echocardiographic study. Int J Cardiol 124:121–123CrossRefPubMed Nemes A, Gavallér H, Csajbók E, Julesz J, Forster T, Csanády M (2008) Aortic stiffness is increased in acromegaly—a transthoracic echocardiographic study. Int J Cardiol 124:121–123CrossRefPubMed
37.
Zurück zum Zitat Boger RH (2006) Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med 38:126–136CrossRefPubMed Boger RH (2006) Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med 38:126–136CrossRefPubMed
38.
Zurück zum Zitat Ronconi V, Giacchetti G, Mariniello B, Camilletti A, Mantero F, Boscaro M, Vignini A, Mazzanti L (2005) Reduced nitric oxide levels in acromegaly: cardiovascular implications. Blood Press 14:227–232CrossRefPubMed Ronconi V, Giacchetti G, Mariniello B, Camilletti A, Mantero F, Boscaro M, Vignini A, Mazzanti L (2005) Reduced nitric oxide levels in acromegaly: cardiovascular implications. Blood Press 14:227–232CrossRefPubMed
39.
Zurück zum Zitat Anagnostis P, Efstathiadou ZA, Gougoura S, Polyzos SA, Karathanasi E, Dritsa P, Kita M, Koukoulis GN (2013) Oxidative stress and reduced antioxidative status, along with endothelial dysfunction in acromegaly. Horm Metab Res 45:314–318PubMed Anagnostis P, Efstathiadou ZA, Gougoura S, Polyzos SA, Karathanasi E, Dritsa P, Kita M, Koukoulis GN (2013) Oxidative stress and reduced antioxidative status, along with endothelial dysfunction in acromegaly. Horm Metab Res 45:314–318PubMed
40.
Zurück zum Zitat Paisley AN, Izzard AS, Gemmell I, Cruickshank K, Trainer PJ, Heagerty AM (2009) Small vessel remodeling and impaired endothelial-dependent dilatation in subcutaneous resistance arteries from patients with acromegaly. J Clin Endocrinol Metab 94:1111–1117CrossRefPubMed Paisley AN, Izzard AS, Gemmell I, Cruickshank K, Trainer PJ, Heagerty AM (2009) Small vessel remodeling and impaired endothelial-dependent dilatation in subcutaneous resistance arteries from patients with acromegaly. J Clin Endocrinol Metab 94:1111–1117CrossRefPubMed
41.
Zurück zum Zitat Maison P, Démolis P, Young J, Schaison G, Giudicelli JF, Chanson P (2000) Vascular reactivity in acromegalic patients: preliminary evidence for regional endothelial dysfunction and increased sympathetic vasoconstriction. Clin Endocrinol 53:445–451CrossRef Maison P, Démolis P, Young J, Schaison G, Giudicelli JF, Chanson P (2000) Vascular reactivity in acromegalic patients: preliminary evidence for regional endothelial dysfunction and increased sympathetic vasoconstriction. Clin Endocrinol 53:445–451CrossRef
42.
Zurück zum Zitat Schutte AE, Volpe M, Tocci G, Conti E (2014) Revisiting the relationship between blood pressure and insulin-like growth factor-1. Hypertension 63:1070–1077CrossRefPubMed Schutte AE, Volpe M, Tocci G, Conti E (2014) Revisiting the relationship between blood pressure and insulin-like growth factor-1. Hypertension 63:1070–1077CrossRefPubMed
43.
Zurück zum Zitat Sherlock M, Reulen RC, Aragon-Alonso A, Ayuk J, Clayton RN, Sheppard MC, Hawkins MM, Bates AS, Stewart PM (2014) A paradigm shift in the monitoring of patients with acromegaly: last available growth hormone may overestimate risk. J Clin Endocrinol Metab 992:478–485CrossRef Sherlock M, Reulen RC, Aragon-Alonso A, Ayuk J, Clayton RN, Sheppard MC, Hawkins MM, Bates AS, Stewart PM (2014) A paradigm shift in the monitoring of patients with acromegaly: last available growth hormone may overestimate risk. J Clin Endocrinol Metab 992:478–485CrossRef
44.
Zurück zum Zitat Baykan M, Erem C, Gedikli O, Hacihasanoglu A, Erdogan T, Kocak M, Kaplan S, Korkmaz L, Celik S (2009) Impairment in flow-mediated vasodilatation of the brachial artery in acromegaly. Med Princ Pract 18:228–232CrossRefPubMed Baykan M, Erem C, Gedikli O, Hacihasanoglu A, Erdogan T, Kocak M, Kaplan S, Korkmaz L, Celik S (2009) Impairment in flow-mediated vasodilatation of the brachial artery in acromegaly. Med Princ Pract 18:228–232CrossRefPubMed
45.
Zurück zum Zitat Găloiu S, Jurcuţ R, Vlădaia A, Florian A, Purice M, Popescu BA, Ginghină C, Coculescu M (2012) Structural and functional changes of carotid wall properties in patients with acromegaly are not restored after 1 year of GH/IGF1 normalization. Exp Clin Endocr Diabetes 120:238–243CrossRef Găloiu S, Jurcuţ R, Vlădaia A, Florian A, Purice M, Popescu BA, Ginghină C, Coculescu M (2012) Structural and functional changes of carotid wall properties in patients with acromegaly are not restored after 1 year of GH/IGF1 normalization. Exp Clin Endocr Diabetes 120:238–243CrossRef
46.
Zurück zum Zitat Smith JC, Lane H, Davies N, Evans LM, Cockcroft J, Scanlon MF, Davies JS (2003) The effects of depot long-acting somatostatin analog on central aortic pressure and arterial stiffness in acromegaly. J Clin Endocrinol Metab 88:2556–2561CrossRefPubMed Smith JC, Lane H, Davies N, Evans LM, Cockcroft J, Scanlon MF, Davies JS (2003) The effects of depot long-acting somatostatin analog on central aortic pressure and arterial stiffness in acromegaly. J Clin Endocrinol Metab 88:2556–2561CrossRefPubMed
47.
Zurück zum Zitat Irving RJ, Carson MN, Webb DJ, Walker BR (2002) Peripheral vascular structure and function in men with contrasting GH levels. J Clin Endocrinol Metab 87:3309–3314CrossRefPubMed Irving RJ, Carson MN, Webb DJ, Walker BR (2002) Peripheral vascular structure and function in men with contrasting GH levels. J Clin Endocrinol Metab 87:3309–3314CrossRefPubMed
Metadaten
Titel
Arterial properties in acromegaly: relation to disease activity and associated cardiovascular risk factors
verfasst von
Marianna Yaron
Elena Izkhakov
Jessica Sack
Ibrahim Azzam
Etty Osher
Karen Tordjman
Naftali Stern
Yona Greenman
Publikationsdatum
12.02.2016
Verlag
Springer US
Erschienen in
Pituitary / Ausgabe 3/2016
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-016-0710-9

Weitere Artikel der Ausgabe 3/2016

Pituitary 3/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.